Sirukumab and adalimumab reduce power Doppler ultrasound signal in patients with rheumatoid arthritis by 4 weeks in a phase III trial. Issue 10 (24th April 2019) - Sweet, Kristen; Dasgupta, Bidisha; de Vries, Dick; Gourley, Ian; Hsu, Benjamin; Loza, Matthew J; Taylor, Peter C